Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocugen (OCGN) EBITDA (2016 - 2025)

Historic EBITDA for Ocugen (OCGN) over the last 12 years, with Q3 2025 value amounting to -$20.0 million.

  • Ocugen's EBITDA fell 5418.11% to -$20.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$64.0 million, marking a year-over-year decrease of 2509.78%. This contributed to the annual value of -$54.0 million for FY2024, which is 1435.86% up from last year.
  • Ocugen's EBITDA amounted to -$20.0 million in Q3 2025, which was down 5418.11% from -$14.8 million recorded in Q2 2025.
  • Ocugen's EBITDA's 5-year high stood at -$7.1 million during Q1 2021, with a 5-year trough of -$26.0 million in Q2 2021.
  • In the last 5 years, Ocugen's EBITDA had a median value of -$15.3 million in 2024 and averaged -$16.4 million.
  • In the last 5 years, Ocugen's EBITDA plummeted by 61809.63% in 2021 and then soared by 5099.12% in 2023.
  • Ocugen's EBITDA (Quarter) stood at -$14.6 million in 2021, then plummeted by 53.61% to -$22.4 million in 2022, then soared by 50.99% to -$11.0 million in 2023, then fell by 26.22% to -$13.9 million in 2024, then plummeted by 44.39% to -$20.0 million in 2025.
  • Its EBITDA was -$20.0 million in Q3 2025, compared to -$14.8 million in Q2 2025 and -$15.4 million in Q1 2025.